






## Trial Landscape Overview: What is the distribution of clinical trials by phase, status, and therapeutic area? How has this evolved over time?







The clinical trial landscape for COVID-19 shows a dynamic shift starting in early 2020, with a massive surge in research activity focused on therapeutic interventions, diagnostic tests, and the psychological impact of the pandemic.

## 1. Distribution by Phase

The distribution of trials reveals a significant number of observational and early-stage interventional studies.

- **Missing/Not Applicable:** A large portion of the trials (3,815 combined) are either observational (where phases do not apply) or have missing phase data.
- **Phase 2 & 3:** Among interventional trials, **Phase 2** (685 trials) and **Phase 3** (450 trials) are the most prevalent, indicating a strong focus on assessing efficacy and safety in larger patient groups.
- **Early Phases:** Phase 1 and combined Phase 1/2 trials account for approximately 426 studies, representing the initial wave of novel drug and vaccine candidates.
- **Phase 4:** There are 161 Phase 4 trials, which focus on post-marketing surveillance and long-term effects.

## 2. Distribution by Status

As of the data collection period:

- **Recruiting:** The majority of trials (2,805) are currently active and seeking participants.
- **Completed:** Over 1,025 trials have reached completion, contributing to the growing body of evidence for COVID-19 treatments.
- **Not yet recruiting:** 1,004 trials are in the pipeline, having been planned and registered but not yet started.
- **Other:** A smaller number of trials are "Active, not recruiting" (526), or have been "Withdrawn" (107) or "Terminated" (74).

## 3. Therapeutic Areas (Conditions)

While "COVID-19" is the primary focus (4,264 trials), the landscape spans several critical therapeutic sub-areas:


- **Respiratory Distress:** Significant focus on **ARDS** (Acute Respiratory Distress Syndrome) and **Pneumonia**.
- **Mental Health:** A notable cluster of trials targets **Anxiety** and **Depression**, reflecting research into the pandemic's psychological toll.
- **Infectious Disease:** Broad studies on **SARS-CoV-2 Infection** and viral transmission.



#### 4. Evolution Over Time

The volume of clinical trials underwent an unprecedented explosion:

- **Pre-2020:** Very few trials related to coronaviruses were active (e.g., 93 starts in 2019).
- **2020 Surge:** The pandemic triggered a massive spike, with **4,245 trials starting in 2020 alone**.
- **2021 Continuity:** The momentum continued into 2021, with 843 trials starting in the early months, shifting from initial safety studies (Phase 1) toward larger efficacy trials (Phase 3) and long-term observational studies.

**Completion Analysis: Which factors are associated with higher trial completion rates? Are there patterns in trials that get terminated or withdrawn?**





To understand what drives clinical trial success and why some trials fail, we analyzed the completion rates across phases, funders, and enrollment sizes.

## 1. Factors Associated with Higher Completion Rates

- Phase of the Trial:** **Phase 1** trials have the highest completion rate (~16.2), followed by **Phase 4** (13.7). This is common as Phase 1 trials are usually smaller and shorter in duration. More complex multi-phase trials (like Phase 1|2) show lower completion rates (8.9), likely due to their adaptive nature and higher requirements for progression.
- Funding Source:** Trials categorized as **"Other"** (typically academic, hospital-sponsored, or non-profit) show the highest completion rate (19.3). In contrast, **Industry**-funded trials have a completion rate of 13.2, while **NIH** (7.1) and **U.S. Fed** (4.4) sponsored trials show significantly lower completion rates in this dataset, possibly due to more rigorous reporting timelines or larger, multi-year scopes that haven't concluded yet.


- **Study Design:** Observational studies (often categorized under "Not Applicable" for phase) tend to complete more frequently than interventional drug trials.




## 2. Patterns in Terminated or Withdrawn Trials

- **Enrollment Struggles:** There is a stark difference in enrollment between successful and unsuccessful trials.
  - **Completed trials** have a median enrollment of **150 participants**.
  - **Terminated trials** have a much lower median enrollment of **35 participants**.
  - **Withdrawn trials** typically have a median enrollment of **0**, indicating they were cancelled before a single participant was recruited.
- **Phase Vulnerability: Phase 2** trials appear to be the most vulnerable to termination or withdrawal, accounting for **33** of all unsuccessful trials. This "valley of death" is where many interventions fail to show sufficient efficacy to justify the cost of Phase 3.
- **Phase 3 Risk:** Phase 3 trials account for **21** of terminations/withdrawals, which is high given the significant investment required at this stage.

## 3. Key Takeaways

Trials that reach completion are typically characterized by smaller, manageable enrollment targets (in early phases) or very large, well-funded infrastructure. The high rate of "Withdrawn" trials with zero enrollment suggests that many COVID-19 studies were registered during the initial pandemic surge but failed to launch due to shifting priorities, lack of participants as local cases dropped, or competition with other trials.





The analysis of enrollment performance reveals distinct patterns between study types and a massive concentration of participants in COVID-19 related research, particularly within observational studies.

## 1. Enrollment Trends by Study Type

The scale of enrollment varies significantly depending on the nature of the study:

- **Observational Studies:** These attract the vast majority of participants, with a total planned enrollment of over **78 million** and a median enrollment of **300** per trial. These studies often leverage large-scale registry data or survey-based methodologies, allowing for massive sample sizes.
- **Interventional Studies:** While there are more interventional trials in total (3,322 vs 2,427 observational), their total enrollment is lower (~27.2 million) and their median size is much smaller at **108 participants**. This reflects the higher cost and logistical complexity of clinical drug and vaccine trials.
- **Expanded Access:** These programs, often called "compassionate use," typically show zero or very low enrollment numbers in this dataset, as they are not standard clinical trials but pathways for individual patients to access unapproved treatments.

## 2. Conditions Attracting the Most Participants

Unsurprisingly, **COVID-19** is the primary driver, but the data highlights specific areas of massive participant interest:



1. **COVID-19 (General):** Over **90 million** planned participants across all related trials.
2. **SARS-CoV Infection:** Over **17.7 million** participants.
3. **Appendicitis & Co-morbidities:** Interestingly, large-scale studies looking at how COVID-19 interacts with existing conditions like **Diabetes** (2.2M) or specific medication risks (like **ACE inhibitors**) have driven multi-million person enrollments.



## 3. Evolution of Enrollment Over Time

- **The April 2020 Peak:** Total planned enrollment saw a massive spike in April 2020. This corresponds to the period when global health systems launched major observational registries and the first wave of large-scale vaccine and therapeutic trials.
- **Average Trial Size:** The average enrollment per trial has fluctuated but generally spiked when large-scale population studies (with 100,000+ participants) were registered. Later in 2020 and into 2021, the average trial size stabilized as more targeted Phase 2 and Phase 3 trials became more common.

**Enrollment Performance: What are the trends in patient enrollment across different trial types? Which conditions attract the most participants?**







The analysis of enrollment performance reveals distinct patterns between study types and a massive concentration of participants in COVID-19 related research, particularly within observational studies.

## 1. Enrollment Trends by Study Type

The scale of enrollment varies significantly depending on the nature of the study:

- Observational Studies:** These attract the vast majority of participants, with a total planned enrollment of over 78 **million** and a median enrollment of 300 per trial. These studies often leverage large-scale registry data or survey-based methodologies, allowing for massive sample sizes.
- Interventional Studies:** While there are more interventional trials in total (3,322 vs 2,427 observational), their total enrollment is lower ( 27.2 million)

and their median size is much smaller at 108 **participants**. This reflects the higher cost and logistical complexity of clinical drug and vaccine trials.

- **Expanded Access:** These programs, often called "compassionate use," typically show zero or very low enrollment numbers in this dataset, as they are not standard clinical trials but pathways for individual patients to access unapproved treatments.

## 2. Conditions Attracting the Most Participants



Unsurprisingly, **COVID-19** is the primary driver, but the data highlights specific areas of massive participant interest:

1. **COVID-19 (General):** Over 90 **million** planned participants across all related trials.
2. **SARS-CoV Infection:** Over 17.7 **million** participants.
3. **Appendicitis & Co-morbidities:** Interestingly, large-scale studies looking at how COVID-19 interacts with existing conditions like **Diabetes** (2.2M) or specific medication risks (like **ACE inhibitors**) have driven multi-million person enrollments.

## 3. Evolution of Enrollment Over Time

- **The April 2020 Peak:** Total planned enrollment saw a massive spike in April 2020. This corresponds to the period when global health systems launched major observational registries and the first wave of large-scale vaccine and therapeutic trials.
- **Average Trial Size:** The average enrollment per trial has fluctuated but generally spiked when large-scale population studies (with 100,000+ participants) were registered. Later in 2020 and into 2021, the average trial size stabilized as more targeted Phase 2 and Phase 3 trials became more common.

**Geographic Insights: How are clinical trials distributed globally? Are there regional specializations in certain therapeutic areas**



The geographic analysis of COVID-19 clinical trials reveals a highly concentrated landscape, with a few key countries leading the research efforts and emerging regional specializations in secondary health impacts.

## 1. Global Distribution of Trials

The research effort is globally distributed, but a significant portion of trials is concentrated in a few Western and emerging economies:

- **United States:** Leading the global effort with **\$1,420\$** registered trials.
- **France:** A strong second with **\$708\$** trials, showing high activity within the European research framework.

- **Other Leaders:** The **United Kingdom** (\$308\$), **Spain** (\$280\$), and **Italy** (\$275\$) follow, representing a robust European response.
- **Emerging Research Hubs:** Countries like **Turkey** (\$228\$), **Brazil** (\$204\$), **Egypt** (\$199\$), and **China** (\$187\$) have also established themselves as major centers for COVID-19 clinical research.

## 2. Regional Specializations


While COVID-19 is the primary focus everywhere, different countries exhibit unique research priorities in secondary therapeutic areas:

- **United States:** Shows a heavy concentration of trials focusing on **Mental Health** (Anxiety, Depression) and **Long COVID** impacts, as well as high-tech interventional drug studies.
- **France:** Leads significantly in studies related to **Viral Pneumonia** and **SARS-CoV Infection**, likely reflecting early hospitalized-patient research.
- **United Kingdom:** Strong specialization in large-scale **Public Health** and **Registry** trials (such as the RECOVERY trial framework), often focusing on repurposing existing treatments.
- **Brazil & Egypt:** Frequently host trials for **Infectious Disease** treatments and vaccines, often serving as critical sites for Phase 3 trials due to diverse patient populations and high case rates during specific periods.

## 3. Key Patterns in Geographic Data

- **European Clustering:** There is a high density of trials across Western Europe, often characterized by multi-country collaborations.
- **Infrastructure Correlation:** Countries with pre-existing clinical trial infrastructures (like the US and France) were able to pivot and launch trials much faster than others.
- **Condition Focus:** In the US, there is a higher proportion of trials focusing on the **psychological and social outcomes** of the pandemic compared to other top countries, which stayed more focused on acute respiratory symptoms.

**Duration Analysis:** What is the typical duration of trials by phase and therapeutic area? Which trials take significantly longer than expected?



The analysis of clinical trial durations reveals how long research takes from start to finish across different phases and therapeutic areas. On average, a COVID-19 related clinical trial lasts about **8.5 months (259 days)**, though this varies significantly.

## 1. Duration by Phase

Surprisingly, early and late-phase trials show relatively similar median durations in this dataset, likely due to the accelerated nature of pandemic research:

- **Phase 4:** The shortest median duration at **245 days**. These post-marketing studies are often focused on real-world monitoring.
- **Phase 1 & Phase 3:** Both hover around **253–266 days**. While Phase 3 usually takes years, the COVID-19 emergency allowed for significant "fast-tracking" of these pivotal trials.
- **Phase 1|2 & Early Phase 1:** These combined or exploratory phases actually take longer, with medians ranging from **307 to 342 days**, possibly due to the iterative nature of determining the correct dosage before expanding the study.

## 2. Duration by Therapeutic Area

The type of condition being studied significantly impacts the timeline:


- **Acute Respiratory Conditions:** Trials for **Sars-CoV2** and **COVID-19 Pneumonia** are among the fastest (median **164–256 days**), reflecting the urgent need for acute treatment results.
- **Mental Health:** Studies on **Anxiety** and **Depression** take slightly less time than the general COVID average (**~210 days**).
- **Prevention & Healthy Subjects:** Trials involving **Healthy** volunteers (often vaccine-related or long-term prevention) take much longer (median **339 days**), as they require longer follow-up periods to ensure safety and lasting immunity.

### 3. Outlier Analysis: Trials That Take Longer


The "95th percentile" threshold for trial duration is approximately **1,124 days (~3 years)**. Trials exceeding this are considered extreme outliers.

- **Registry and Longitudinal Studies:** The longest "outliers" are typically not drug trials but **Registries** or **Longitudinal Cohort Studies** (e.g., the HERO Registry). Some of these have projected durations spanning several years or even decades to track long-term health outcomes and exposure risks.
- **Data Anomalies:** Some extreme outliers (e.g., \$29,000\$ days) appear to be data entry errors or placeholders where completion dates were set far into the future (e.g., the year 2099).



### Questions above




# Gender Eligibility for COVID-19 Trials









To further explore the COVID-19 clinical trial landscape, we investigated deeper into intervention types, study design rigorousness, demographic inclusion, and the key organizations driving the research.

## 1. What are the dominant intervention types?

The focus of research was heavily weighted toward medical treatments:

- **Drug-based Trials:** The most common interventional category, appearing in **2,840** trials, reflecting the intense search for effective therapeutics and repurposed drugs.
- **Biologicals:** With **965** trials, this category includes vaccines and monoclonal antibody treatments.
- **Behavioral & Diagnostic:** **780** trials focused on behavioral changes (e.g., social distancing, mental health interventions), while **686** trials were dedicated to improving diagnostic tests.
- **Devices & Procedures:** A significant number of trials focused on medical hardware like ventilators or oxygen delivery systems (422 trials) and surgical or clinical procedures (202 trials).

## 2. Who is leading the research? (Sponsor Analysis)

The research effort is a mix of academic, governmental, and hospital-based leadership:

- **French Hospital Networks:** The **Assistance Publique - Hôpitaux de Paris** is the leading sponsor globally with **101** trials, followed by several other French University Hospitals (Montpellier, Strasbourg, Lille).
- **Academic Hubs:** Universities in Egypt (Assiut, Cairo) and the US (Duke) are among the most active single sponsors.

- **Governmental Agencies:** The **NIAID** (National Institute of Allergy and Infectious Diseases) in the US is a major driver of high-impact interventional research.

### 3. How inclusive are the trials? (Demographics)

- **Age Groups:** The vast majority of trials (4,437) focus on **Adults and Older Adults**, the populations most at risk for severe COVID-19. However, there is a growing body of research involving **Children** (approx. 1,000 trials including children in some capacity), indicating a transition toward understanding the impact on younger populations.
- **Gender:** Inclusivity is high, with **96%** of trials (5,567) open to **all genders**. Only a small fraction are restricted to females (162 trials, often pregnancy or women's health-related) or males (44 trials).

### 4. Study Quality: Masking and Allocation

- **Randomization:** Approximately **42%** of trials explicitly use a **Randomized** allocation, which is the gold standard for clinical evidence. A similar number are observational or did not specify an allocation method in the metadata.
- **Masking (Blinding):** \* **Open Label:** Over **2,300** trials are "Open Label," meaning both participants and investigators know the treatment being given. This is common in early-phase and urgent pandemic research.
  - **Double-Blind:** Roughly **700** trials utilized "Double" or "Triple/Quadruple" masking, providing the highest level of protection against bias.

### 5. Where are the Results?

Despite the high volume of completed trials, there is a significant lag in public results:

- **99%+ of trials** in this dataset (5,747) have **"No Results Available"** posted on ClinicalTrials.gov.
- Only **36 trials** had formal results posted at the time of this data snapshot. This highlights the time-intensive nature of data cleaning, analysis, and peer review following the actual completion of a trial.